Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06192797 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma

Study acronym: CCGLC-013
StatusRecruiting
PhasePhase 2
Started2024-06-04
View on ClinicalTrials.gov ↗

Amendment history

2026-07-21
Study Identification, Study Status, Oversight, IPDSharing v5
Primary completion date2026-12-31→2028-06-30
Completion date2028-06-30→2029-06-30
Start date2024-06-11→2024-06-04
Study titlerevised
Combined HAIC, Lenvatinib and Pucotenlimab Asas Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma
2024-11-01
Study Status, Eligibility v4
Re-verified, no change to tracked fields
2024-10-11
Study Identification, Study Status, Sponsor/Collaborators, Oversight, IPDSharing v3
Primary completion date2025-12-31→2026-12-31
Completion date2026-06-01→2028-06-30
Start date2024-06-04→2024-06-11
Lead sponsorZe-yang Ding, MD→Tongji Hospital
Collaborators-67 characters
Geneplus-Beijing Co. Ltd. Chinese Cooperative Group of Liver Cancer
Study titlerevised
Combined HAIC, Lenvatinib and Pucotenlimab asAs Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma
2024-06-12
Study Status v2
Start dateestimated 2024-01-31→confirmed 2024-06-04
2024-01-12
Study Status, Sponsor/Collaborators v1
Start date2023-12-31→2024-01-31
Collaborators3 to 2 entries
Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province
2023-12-21
Original filing
This is an open-label, single-arm, phase 2 study. The purpose of study is to evaluate the feasibility and safety of hepatic artery infusion chemotherapy combined with lenvatinib and pucotenlimab as conversion therapy for unresectable intrahepatic cholangiocarcinoma.
Trial Details
NCT Number NCT06192797
Lead Sponsor Tongji Hospital
Conditions Cholangiocarcinoma Non-resectable
Enrollment 36 participants
Start Date 2024-06-04
Primary Completion 2028-06-30 (estimated)
Study Completion 2029-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-22